<DOC>
	<DOCNO>NCT01107717</DOCNO>
	<brief_summary>Type 2 diabetes systemic metabolic disease significant morbidity mortality due damage blood vessel . Increased blood sugar level hallmark diabetes contributes development many complication . Multiple defect , e.g . impaired insulin secretion impaired insulin action , contribute development disease . The aim study test efficacy durability combination drug correct defect lead development diabetes achieve adequate durable control blood sugar level . Achieving adequate durable control blood sugar prevent many diabetes complication .</brief_summary>
	<brief_title>Durability Combination Therapy With Exenatide/Pioglitazone/Metformin v . Conventional Therapy New Onset T2DM</brief_title>
	<detailed_description />
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>subject type 2 diabetes diagnose past 2 year , 18 year age , drug naive , metformin less 3 month subject type 1 diabetes GAD positive subject subject long stand diabetes ( &gt; 2 year ) subject drug naive metformin 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>new onset</keyword>
	<keyword>combination therapy</keyword>
	<keyword>new onset type 2 diabetes</keyword>
</DOC>